Marion Refici

447 total citations
8 papers, 354 citations indexed

About

Marion Refici is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Marion Refici has authored 8 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Molecular Biology and 2 papers in Hematology. Recurrent topics in Marion Refici's work include Cancer therapeutics and mechanisms (2 papers), Acute Myeloid Leukemia Research (1 paper) and Cell death mechanisms and regulation (1 paper). Marion Refici is often cited by papers focused on Cancer therapeutics and mechanisms (2 papers), Acute Myeloid Leukemia Research (1 paper) and Cell death mechanisms and regulation (1 paper). Marion Refici collaborates with scholars based in United States and United Kingdom. Marion Refici's co-authors include David J. Frost, Saul H. Rosenberg, Anatol Oleksijew, Steven W. Elmore, Michael J. Mitten, Scott Ackler, Christin Tse, Stephen W. Fesik, Joy Bauch and Alex R. Shoemaker and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and American Journal of Physiology-Regulatory, Integrative and Comparative Physiology.

In The Last Decade

Marion Refici

8 papers receiving 348 citations

Peers

Marion Refici

MB

ONCOL

PFM

IMMUN

GENET

J Y J Wang United States

Baole Wang United States

Dejan Radeski Australia

Thomas Mehrling United Kingdom

Laura Bonmassar Italy

Zohar Sachs United States

Britta Lamottke Germany

Jennifer Kimberly Lue United States

Qiuyun Luo China

Julia Claasen Germany

J Y J Wang United States

Marion Refici

255 ×0.9

MB

231 ×1.7

ONCOL

61 ×1.2

PFM

32 ×0.6

IMMUN

25 ×0.6

GENET

Citations per year, relative to Marion Refici Marion Refici (= 1×) peers J Y J Wang

Countries citing papers authored by Marion Refici

Since Specialization

Citations

This map shows the geographic impact of Marion Refici's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marion Refici with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marion Refici more than expected).

Fields of papers citing papers by Marion Refici

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marion Refici. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marion Refici. The network helps show where Marion Refici may publish in the future.

Co-authorship network of co-authors of Marion Refici

This figure shows the co-authorship network connecting the top 25 collaborators of Marion Refici. A scholar is included among the top collaborators of Marion Refici based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marion Refici. Marion Refici is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Refici, Marion, Ziping Yang, Jacob Riehm, et al.. (2022). Abstract 5339: BCL2A1 is expressed in myelofibrosis specimens and JAK2-mutated UKE-1 cells, yet does not inhibit synergistic cell killing by BCL-XL inhibitor navitoclax plus JAK1/2 inhibitors, including ruxolitinib. Cancer Research. 82(12_Supplement). 5339–5339. 2 indexed citations

2.

Ackler, Scott, Michael J. Mitten, Kelly Foster, et al.. (2010). The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemotherapy and Pharmacology. 66(5). 869–880. 100 indexed citations

3.

Ackler, Scott, Xiao Yu, Michael J. Mitten, et al.. (2008). ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics. 7(10). 3265–3274. 64 indexed citations

4.

Shoemaker, Alex R., Michael J. Mitten, Jessica Adickes, et al.. (2008). Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models. Clinical Cancer Research. 14(11). 3268–3277. 155 indexed citations

5.

Ferguson, Debra C., Luis E. Rodrı́guez, Joann P. Palma, et al.. (2005). Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models. Clinical Cancer Research. 11(8). 3045–3054. 20 indexed citations

6.

Joseph, Ingrid B.J., David Ferguson, Joann P. Palma, et al.. (2004). 473 Poly(ADP-ribose) polymerase inhibitor, ABT-472 enhances antitumor activity of doxorubicin in human xenograft models and protects against drug-induced cardiac toxicity. European Journal of Cancer Supplements. 2(8). 144–144. 4 indexed citations

7.

Refici, Marion, Dennis W. Metzger, Bernard P. Arulanandam, Michelle R. Lennartz, & Daniel J. Loegering. (2001). Fcγ-receptor signaling augments the LPS-stimulated increase in serum tumor necrosis factor-α levels. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 280(4). R1037–R1044. 8 indexed citations

8.

Loegering, Daniel J. & Marion Refici. (1999). IgG-COATED ERYTHROCYTES AUGMENT THE LPS-STIMULATED INCREASE IN SERUM TNF LEVELS VIA Fcy RECEPTORS. Shock. 11(Supplement). 23–23. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact